First-Line Treatment for Metastatic Renal Cell Carcinoma — Non-Clear-Cell Subtypes (Chromophobe, Unclassified)

This protocol covers first-line systemic management for patients with metastatic renal cell carcinoma of a non-clear-cell histology other than papillary — specifically subtypes such as chromophobe and unclassified RCC.

Clinical Scenario

The patient presents with metastatic renal cell carcinoma confirmed as a non-clear-cell subtype other than papillary — for example, chromophobe or unclassified histology. This population is distinct from both clear-cell and papillary RCC and requires a dedicated treatment approach. The applicable regimen depends on the precise histological subtype identified.

Treatment Approach

First-line options for this population include targeted therapy and immunotherapy-based combinations. Eligible regimens differ based on the confirmed histological subtype — for instance, not all options apply equally across chromophobe and unclassified variants. The complete selection criteria and evidence-based regimen algorithm are in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

Offer sunitinib to patients with other non-clear cell renal cell carcinoma (cc-RCC) subtypes than papillary RCC.

Offer lenvatinib plus pembrolizumab to patients with non-ccRCC subtypes.

Offer nivolumab plus ipilimumab in patients with non-ccRCC.

Offer cabozantinib and nivolumab to patients with non-ccRCC subtypes other than chromophobe RCC.

View source ↗